Analysts Issue Forecasts for Medexus Pharmaceuticals Inc.’s Q2 2025 Earnings (TSE:MDP)

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Leede Financial issued their Q2 2025 earnings estimates for shares of Medexus Pharmaceuticals in a research note issued to investors on Monday, September 30th. Leede Financial analyst D. Loe forecasts that the company will post earnings of $0.11 per share for the quarter. Leede Financial currently has a “Speculative Buy” rating and a $8.25 price target on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals’ Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at $0.34 EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at $0.23 EPS, Q1 2027 earnings at $0.11 EPS, Q2 2027 earnings at $0.12 EPS, FY2027 earnings at $0.56 EPS and FY2028 earnings at $0.79 EPS.

A number of other equities analysts also recently commented on MDP. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, June 26th. Stifel Canada raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus upped their price objective on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Medexus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of C$5.25.

Medexus Pharmaceuticals Trading Down 2.6 %

MDP opened at C$2.58 on Wednesday. The company has a market capitalization of C$63.29 million, a price-to-earnings ratio of 51.60 and a beta of 1.95. Medexus Pharmaceuticals has a 12-month low of C$1.44 and a 12-month high of C$3.39. The business’s fifty day simple moving average is C$2.45 and its 200-day simple moving average is C$1.99.

Medexus Pharmaceuticals (TSE:MDP) last posted its quarterly earnings results on Wednesday, August 7th. The company reported C$0.11 EPS for the quarter, topping analysts’ consensus estimates of C$0.04 by C$0.07. The firm had revenue of C$37.33 million for the quarter, compared to analysts’ expectations of C$36.95 million. Medexus Pharmaceuticals had a net margin of 1.00% and a return on equity of 3.95%.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.